FDA extends priority review of oral MS drug Cladribine
FDA extends priority review of oral MS drug Cladribine
The U.S. drugs watchdog will take more time to decide over Merck KGaA's multiple sclerosis (MS) pill, the German company said on Friday, two months after drawing a rejection from European regulators.
The U.S. Food and Drug Administration (FDA) extended its review period for cladribine pills as a therapy for relapsing forms of (MS) by three months to Feb. 28, 2011, Merck said.
"The FDA extended the review period to provide additional time for a full review of additional information provided under the new drug application," the company added.... [Read More] - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1951 Views
-
Last post by frodo
-
- 0 Replies
- 1250 Views
-
Last post by frodo
-
- 0 Replies
- 2117 Views
-
Last post by NHE
-
- 1 Replies
- 1799 Views
-
Last post by frodo
-
- 0 Replies
- 1325 Views
-
Last post by NHE
-
- 0 Replies
- 1699 Views
-
Last post by frodo
-
- 0 Replies
- 2551 Views
-
Last post by NHE
-
- 1 Replies
- 1520 Views
-
Last post by NHE
-
- 0 Replies
- 1080 Views
-
Last post by frodo